CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION


Condition: D011471, D064129, D035683, D009360, D014408

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT04188275

Sponsor: Azienda Ospedaliero-Universitaria Careggi

Phase:

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • Castration Resistant Prostate Cancer defined as biochemical or clinical progression under therapy with LHRH agonist and castrate plasma testosterone levels (<20 ng/dl or <1.73 nmol/L)
  • Eligible for medical treatment
  • Age >18 years
  • Informed consentment

Exclusion Criteria:

  • Medical contraindication/refusal to chemotherapy or endocrine therapy
  • Life expectancy inferior to 1 year
  • Previously diagnosed neoplasm

View trial on ClinicalTrials.gov